Comparison between efficacy of triamcinolone acetonide and bevacizumab in a case with type 2a idiopathic parafoveal telangiectasia/Tip 2 idiopatik parafoveal telenjektazili bir olguda bevacizumab ile triamsinolon asetonidin karsilastirilmasi

Purpose: To compare the efficacy of intravitreal triamcinolone acetonide and bevacizumab in the treatment of a case of type 2A idiopathic parafoveal telangiectasia (IPT). Material and Method: A 55-year-old man with complaint of decreased vision in both eyes was diagnosed as type 2A IPT after a complete ophthalmological examination, fundus fluorescein angiography (FA) and optical coherence tomography (OCT). We injected intravitreally 4 mg /0.1 cc of triamcinolone acetonide into the right eye and 24 hours later 1.25 mg /0.05 cc of bevacizumab into the left eye. The patient was evaluated on the first day, first week, first month, and the third month with FA and OCT. Results: Before treatment, best-corrected visual acuity (BCVA) was 5/100 in the right eye and 5/10 in the left eye. At the first-week post-treatment visit, BCVA improved to 5/10 in the right eye and 10/10 in the left eye. On FA, edema in the temporal foveal area was detected in both eyes. This macular edema began to decrease at the first-week visit. Visual acuity was the same on the first- and third-month visits. The FA findings also remained the same. During this 3-month follow-up period, the patient did not need any other additional treatment. Discussion: Intravitreal injections of triamcinolone acetonide and bevacizumab are optional modalities in the treatment of type 2 IPT. The efficacy and permanence of influence-duration of action of triamcinolone acetonide and bevacizumab were similar in our case. (Turk J Ophthalmol 2011; 41: 6-9) Key Words: Type 2A idiopathic parafoveal telangiectasia, triamcinolone acetonide, bevacizumab Amac: Tip 2 idiopatik Parafoveal Telenjektazili (IPT) bir olgunun tedavisinde intravitreal bevacizumab ile triamsinolon asetonidin etkinliginin karsilastirilmasi. Gerec ve Yontem: Elli bes yasindaki erkek hasta, her iki gozde gorme azalmasi sikayeti ile klinigimize basvurdu. Ayrintili oftalmolojik muayene, fundus floresein anjiografi (FFA) ve optik koherans tomografi (OKT) sonuclarina dayanarak hastaya Tip 2A IPT tanisi kondu. Tedavi olarak hastanin sag gozune intravitreal 4 mg/0,1 cc triamsinolon asetonit, sol gozune ise 24 saat sonra 1,25 mg / 0,05 cc intravitreal bevacizumab uygulandi. Hasta enjeksiyonlardan sonra 1. gun, 1. hafta, 1. ay ve 3.ay sonunda FFA ve OKT ile degerlendirildi. Sonuclar: Tedavi oncesi hastanin en iyi duzeltilmis gorme keskinligi sag gozde 5/100, sol gozde ise 5/10 idi. Tedavi sonrasi birinci haftada hastanin sag gormesi 5/10, solda ise 10/10 ula